An Assay to Identify and Classify Epimutagens
表观诱变剂的识别和分类方法
基本信息
- 批准号:7655389
- 负责人:
- 金额:$ 20万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-08-01 至 2011-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAzacitidineBiological AssayBiological ModelsButyratesCarcinogensCell Culture TechniquesCell LineCell SeparationCell physiologyCellsChemical AgentsChemicalsClone CellsCloningCultured CellsDNADNA SequenceDetectionDevelopmentDiseaseDoseElementsEngineeringEnsureEnvironmental HealthEnvironmental ProtectionEpigenetic ProcessEthionineEukaryotaExhibitsFutureGene MutationGenerationsGenomeGenomicsGrantGreen Fluorescent ProteinsHealthHumanHuman DevelopmentLearningMalignant NeoplasmsMammalian CellMammalsMeasurementMeasuresMethodsMonitorMutagenesisMutagenicity TestsMutagensMutationOrganismPathway interactionsPilot ProjectsPlayPopulationReadingRegulationReporterReporter GenesReportingReproducibilityResearchRoleScreening procedureSiteSystemTechniquesTestingTranscriptional RegulationTransfectionTransgenesTransgenic OrganismsTrichostatin Abasedesignenvironmental agentenvironmental chemicalfollow-uppublic health relevanceresponsesodium arsenitesuccesstooltransgene expression
项目摘要
DESCRIPTION (provided by applicant): This proposal aims to develop a method to screen for chemical agents that disrupt epigenetic processes in mammalian cells. Epigenetics deals with heritable changes to the function of DNA that does not involve altered DNA sequence. In mammals and other multicellular organisms, most of the genome is kept in a silent transcriptional state by epigenetic mechanisms. Disruption of this silent state can have drastic effects, including developmental anomalies and cancer. Some chemicals are known to disrupt epigenetic silencing, but we have no comprehensive picture of the environmental agents that can act as "epimutagens". We hypothesize that there are many chemical epimutagens. In order to facilitate the discovery and study of these agents, we propose to develop a mammalian cell-based system that can screen for epimutagenic activity in mammalian cells. We will adapt a system that we have used extensively to study epigenetic silencing of transgenes in cultured cells. By selecting for cell clones that are sensitive to the disruption of epigenetic silencing by known epimutagens, we will derive a panel of cell lines that can be used to screen for epimutagenic activity in a manner analogous to the Ames test for mutagenicity. PUBLIC HEALTH RELEVANCE: Human development and disease are pervasively affected by epigenetic processes. There may be many environmental agents that are capable of disrupting epigenetic silencing and causing health effects, but we lack the means to readily identify them. We propose to develop a system that will permit screening of large numbers of chemicals for epigenetic effects. PUBLIC HEALTH RELEVANCE: The protection of humans from harmful environmental chemicals requires the existence of means to identify such compounds from among the millions of dietary and industrial chemicals to which people are exposed. Tests for mutagenic compounds-those that cause errors in the sequence of DNA and are therefore carcinogenic-have existed since the 1970s. Another class of potential carcinogen, however, the class of epimutagenic compounds, is currently undetectable; research into and regulation of such compounds is not a routine part of environmental health monitoring. We propose to develop tools for the detection and measurement of epimutagens, ultimately enabling environmental protections to be put in place.
描述(由申请人提供):本提案旨在开发一种筛选破坏哺乳动物细胞表观遗传过程的化学试剂的方法。 表观遗传学研究的是不涉及DNA序列改变的DNA功能的可遗传变化。在哺乳动物和其他多细胞生物中,大部分基因组通过表观遗传机制保持在沉默的转录状态。这种沉默状态的破坏可能会产生严重的影响,包括发育异常和癌症。已知一些化学物质会破坏表观遗传沉默,但我们对可以充当“表观诱变剂”的环境因子没有全面的了解。我们假设有许多化学表突变体。为了促进这些药物的发现和研究,我们建议开发一种基于哺乳动物细胞的系统,可以在哺乳动物细胞中筛选表突变活性。我们将采用一个系统,我们已经广泛用于研究培养细胞中转基因的表观遗传沉默。通过选择对已知表观诱变剂破坏表观遗传沉默敏感的细胞克隆,我们将获得一组细胞系,其可用于以类似于致突变性的艾姆斯试验的方式筛选表观诱变活性。公共卫生相关性:人类发育和疾病普遍受到表观遗传过程的影响。可能有许多环境因子能够破坏表观遗传沉默并造成健康影响,但我们缺乏容易识别它们的方法。我们建议开发一个系统,将允许筛选大量的化学物质的表观遗传效应。公共卫生关系:保护人类免受有害环境化学品的影响需要有手段从人们接触的数百万种饮食和工业化学品中识别出这些化合物。对诱变化合物的测试--那些导致DNA序列错误并因此致癌的化合物--从20世纪70年代就已经存在了。然而,另一类潜在的致癌物,即表突变化合物,目前还无法检测到;对这类化合物的研究和管制并不是环境健康监测的常规部分。我们建议开发用于检测和测量表突变体的工具,最终使环境保护能够到位。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Deficiency of MIWI2 (Piwil4) induces mouse erythroleukemia cell differentiation, but has no effect on hematopoiesis in vivo.
- DOI:10.1371/journal.pone.0082573
- 发表时间:2013
- 期刊:
- 影响因子:3.7
- 作者:Jacobs JE;Wagner M;Dhahbi J;Boffelli D;Martin DI
- 通讯作者:Martin DI
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Ian Kingston Martin其他文献
David Ian Kingston Martin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Ian Kingston Martin', 18)}}的其他基金
A high-throughput screen for candidate agents that may reverse gamma-globin silen
对可能逆转伽马珠蛋白沉默的候选药物进行高通量筛选
- 批准号:
7532720 - 财政年份:2009
- 资助金额:
$ 20万 - 项目类别:
A high-throughput screen for candidate agents that may reverse gamma-globin silen
高通量筛选可能逆转伽马珠蛋白沉默的候选药物
- 批准号:
7851313 - 财政年份:2009
- 资助金额:
$ 20万 - 项目类别:
Epigenetic Suppression of the Obese Yellow Phenotype
肥胖黄色表型的表观遗传抑制
- 批准号:
7102832 - 财政年份:2005
- 资助金额:
$ 20万 - 项目类别:
Germline epimutation of hMLH1 as a factor in HNPCC
hMLH1 种系表突变作为 HNPCC 的一个因素
- 批准号:
7076832 - 财政年份:2005
- 资助金额:
$ 20万 - 项目类别:
Germline epimutation of hMLH1 as a factor in HNPCC
hMLH1 种系表突变作为 HNPCC 的一个因素
- 批准号:
6856870 - 财政年份:2005
- 资助金额:
$ 20万 - 项目类别:
相似国自然基金
CRISPR/Cas9全基因组文库筛选Venetoclax/Azacitidine耐药关键基因及其机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Serial monitoring of circulating cell-free tumor DNA as measured by duplex sequencing in older patients with acute myeloid leukemia who receive azacitidine+venetoclax +/- immune checkpoint blockade
通过双重测序对接受阿扎胞苷维奈托克/免疫检查点阻断的老年急性髓系白血病患者的循环游离肿瘤 DNA 进行连续监测
- 批准号:
10337831 - 财政年份:2021
- 资助金额:
$ 20万 - 项目类别:
Precision Medicine for Myeloid Malignancies with 5-Azacitidine
5-阿扎胞苷用于骨髓恶性肿瘤的精准医学
- 批准号:
422236 - 财政年份:2020
- 资助金额:
$ 20万 - 项目类别:
Fellowship Programs
Precision Medicine for Myeloid Malignancies with 5-Azacitidine
5-阿扎胞苷用于骨髓恶性肿瘤的精准医学
- 批准号:
417283 - 财政年份:2019
- 资助金额:
$ 20万 - 项目类别:
Studentship Programs
Beyond Azacitidine: Investigating new therapeutic targets for the treatment of Myelodysplastic Syndrome
超越阿扎胞苷:研究治疗骨髓增生异常综合征的新治疗靶点
- 批准号:
nhmrc : GNT1163815 - 财政年份:2019
- 资助金额:
$ 20万 - 项目类别:
Project Grants
Clonal Evolution in Myelodysplasia and Acute Myeloid Leukaemia following Azacitidine
阿扎胞苷后骨髓增生异常和急性髓系白血病的克隆进化
- 批准号:
nhmrc : GNT1128984 - 财政年份:2017
- 资助金额:
$ 20万 - 项目类别:
Project Grants
Clonal Evolution in Myelodysplasia and Acute Myeloid Leukaemia following Azacitidine
阿扎胞苷后骨髓增生异常和急性髓系白血病的克隆进化
- 批准号:
nhmrc : 1128984 - 财政年份:2017
- 资助金额:
$ 20万 - 项目类别:
Project Grants
Azacitidine耐性機序の解明に基づく新たな急性白血病治療戦略の確立
阐明阿扎胞苷耐药机制建立急性白血病治疗新策略
- 批准号:
25461435 - 财政年份:2013
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PET Imaging of GVHD and GVL after treatment with Azacitidine
阿扎胞苷治疗后 GVHD 和 GVL 的 PET 成像
- 批准号:
8195498 - 财政年份:2012
- 资助金额:
$ 20万 - 项目类别:
Phase II trial of Azacitidine plus Deferasirox in higher risk Myelodysplastic Syndromes (MDS)
阿扎胞苷加地拉罗司治疗高危骨髓增生异常综合征 (MDS) 的 II 期试验
- 批准号:
243003 - 财政年份:2011
- 资助金额:
$ 20万 - 项目类别:
Fellowship Programs
PET Imaging of GVHD and GVL after treatment with Azacitidine
阿扎胞苷治疗后 GVHD 和 GVL 的 PET 成像
- 批准号:
8567974 - 财政年份:
- 资助金额:
$ 20万 - 项目类别:














{{item.name}}会员




